Equity in access to high cost drugs in Uruguay

Equity in access to high cost drugs in Uruguay

The aim of this study was to determine the equity in access to high cost oncology medicines reimbursed by the Uruguayan National Health System. Also, were determined the causes of access inequities. Different levels of access were determined by crossing epidemiological and reimbursement data with ge...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Value in health regional issues 2015-12, Vol.8, p.122-128
Hauptverfasser: González-Vacarezza, Nicolás, Poggi, Mariana, Arroyo, Gustavo, Muxi, Pablo, Alonso, Isabel, Rodríguez, Robinson, Díaz, Lilián, Signorelli, Silvana
Format: Artikel
Sprache:eng
Schlagworte:
access
drugs
equity
high-cost
Uruguay
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 128
container_issue
container_start_page 122
container_title Value in health regional issues
container_volume 8
creator González-Vacarezza, Nicolás
Poggi, Mariana
Arroyo, Gustavo
Muxi, Pablo
Alonso, Isabel
Rodríguez, Robinson
Díaz, Lilián
Signorelli, Silvana
description The aim of this study was to determine the equity in access to high cost oncology medicines reimbursed by the Uruguayan National Health System. Also, were determined the causes of access inequities. Different levels of access were determined by crossing epidemiological and reimbursement data with geographical distribution and number of Health System users. Possible causes of inequities were determined and weighted by Delphi technique. Access of patients assisted in the public sector to bevacizumab for metastatic colorectal cancer, rituximab for the treatment of non-Hodgkin lymphoma and trastuzumab for advanced HER2+ breast cancer, appears to be lower compared to patients assisted in private sector.Regarding rituximab for the treatment of non-Hodgkin lymphoma and trastuzumab for advanced HER2+ breast cancer, the results seem to show less access for patients residing outside the south region compared to those living in the south region.The main barriers to get reimbursement for patients living outside southern region are the access to pathological anatomy studies, imaging and other clinical analysis. Late diagnosis appears to be the main hurdles in access to these anti-cancer drugs, for patients assisted in the public sector. Equitable access to high cost drugs reimbursed by the National Health System requires policy decisions to address this issue.
doi_str_mv 10.1016/j.vhri.2015.09.006
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2032397621</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2212109915000679</els_id><sourcerecordid>2032397621</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3156-cd2bf79c30ba3c8a2f896715316c0bb8c4ec3288d049c424a5b85059bd7741843</originalsourceid><addsrcrecordid>eNp9kM1rwkAQxZfSUsX6D_RQcuwl6exHNrvQSxH7AUIv9bxsJquuqNHdRPC_b4LaY-cyD-a9B_Mj5JFCRoHKl3V2XAWfMaB5BjoDkDdkyBhlKaXAbq8atB6QcYxr6KYQwBXckwHTUisqxZBk00Prm1Pid4lFdDEmTZ2s_HKVYB2bpArtMvbHeSdae3ogdwu7iW582SMyf5_-TD7T2ffH1-RtliKnuUyxYuWi0MihtByVZQulZUFzTiVCWSoUDjlTqgKhUTBh81LlkOuyKgpBleAj8nzu3Yf60LrYmK2P6DYbu3N1Gw0DzrguJKOdlZ2tGOoYg1uYffBbG06GgulRmbXpUZkelQFtOlRd6OnS35ZbV_1FrmA6w-vZ4Lovj94FE9G7HbrKB4eNqWr_X_8vq-13qg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2032397621</pqid></control><display><type>article</type><title>Equity in access to high cost drugs in Uruguay</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>González-Vacarezza, Nicolás ; Poggi, Mariana ; Arroyo, Gustavo ; Muxi, Pablo ; Alonso, Isabel ; Rodríguez, Robinson ; Díaz, Lilián ; Signorelli, Silvana</creator><creatorcontrib>González-Vacarezza, Nicolás ; Poggi, Mariana ; Arroyo, Gustavo ; Muxi, Pablo ; Alonso, Isabel ; Rodríguez, Robinson ; Díaz, Lilián ; Signorelli, Silvana</creatorcontrib><description>The aim of this study was to determine the equity in access to high cost oncology medicines reimbursed by the Uruguayan National Health System. Also, were determined the causes of access inequities. Different levels of access were determined by crossing epidemiological and reimbursement data with geographical distribution and number of Health System users. Possible causes of inequities were determined and weighted by Delphi technique. Access of patients assisted in the public sector to bevacizumab for metastatic colorectal cancer, rituximab for the treatment of non-Hodgkin lymphoma and trastuzumab for advanced HER2+ breast cancer, appears to be lower compared to patients assisted in private sector.Regarding rituximab for the treatment of non-Hodgkin lymphoma and trastuzumab for advanced HER2+ breast cancer, the results seem to show less access for patients residing outside the south region compared to those living in the south region.The main barriers to get reimbursement for patients living outside southern region are the access to pathological anatomy studies, imaging and other clinical analysis. Late diagnosis appears to be the main hurdles in access to these anti-cancer drugs, for patients assisted in the public sector. Equitable access to high cost drugs reimbursed by the National Health System requires policy decisions to address this issue.</description><identifier>ISSN: 2212-1099</identifier><identifier>EISSN: 2212-1102</identifier><identifier>DOI: 10.1016/j.vhri.2015.09.006</identifier><identifier>PMID: 29698164</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>access ; drugs ; equity ; high-cost ; Uruguay</subject><ispartof>Value in health regional issues, 2015-12, Vol.8, p.122-128</ispartof><rights>2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR)</rights><rights>Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3156-cd2bf79c30ba3c8a2f896715316c0bb8c4ec3288d049c424a5b85059bd7741843</citedby><cites>FETCH-LOGICAL-c3156-cd2bf79c30ba3c8a2f896715316c0bb8c4ec3288d049c424a5b85059bd7741843</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29698164$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>González-Vacarezza, Nicolás</creatorcontrib><creatorcontrib>Poggi, Mariana</creatorcontrib><creatorcontrib>Arroyo, Gustavo</creatorcontrib><creatorcontrib>Muxi, Pablo</creatorcontrib><creatorcontrib>Alonso, Isabel</creatorcontrib><creatorcontrib>Rodríguez, Robinson</creatorcontrib><creatorcontrib>Díaz, Lilián</creatorcontrib><creatorcontrib>Signorelli, Silvana</creatorcontrib><title>Equity in access to high cost drugs in Uruguay</title><title>Value in health regional issues</title><addtitle>Value Health Reg Issues</addtitle><description>The aim of this study was to determine the equity in access to high cost oncology medicines reimbursed by the Uruguayan National Health System. Also, were determined the causes of access inequities. Different levels of access were determined by crossing epidemiological and reimbursement data with geographical distribution and number of Health System users. Possible causes of inequities were determined and weighted by Delphi technique. Access of patients assisted in the public sector to bevacizumab for metastatic colorectal cancer, rituximab for the treatment of non-Hodgkin lymphoma and trastuzumab for advanced HER2+ breast cancer, appears to be lower compared to patients assisted in private sector.Regarding rituximab for the treatment of non-Hodgkin lymphoma and trastuzumab for advanced HER2+ breast cancer, the results seem to show less access for patients residing outside the south region compared to those living in the south region.The main barriers to get reimbursement for patients living outside southern region are the access to pathological anatomy studies, imaging and other clinical analysis. Late diagnosis appears to be the main hurdles in access to these anti-cancer drugs, for patients assisted in the public sector. Equitable access to high cost drugs reimbursed by the National Health System requires policy decisions to address this issue.</description><subject>access</subject><subject>drugs</subject><subject>equity</subject><subject>high-cost</subject><subject>Uruguay</subject><issn>2212-1099</issn><issn>2212-1102</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp9kM1rwkAQxZfSUsX6D_RQcuwl6exHNrvQSxH7AUIv9bxsJquuqNHdRPC_b4LaY-cyD-a9B_Mj5JFCRoHKl3V2XAWfMaB5BjoDkDdkyBhlKaXAbq8atB6QcYxr6KYQwBXckwHTUisqxZBk00Prm1Pid4lFdDEmTZ2s_HKVYB2bpArtMvbHeSdae3ogdwu7iW582SMyf5_-TD7T2ffH1-RtliKnuUyxYuWi0MihtByVZQulZUFzTiVCWSoUDjlTqgKhUTBh81LlkOuyKgpBleAj8nzu3Yf60LrYmK2P6DYbu3N1Gw0DzrguJKOdlZ2tGOoYg1uYffBbG06GgulRmbXpUZkelQFtOlRd6OnS35ZbV_1FrmA6w-vZ4Lovj94FE9G7HbrKB4eNqWr_X_8vq-13qg</recordid><startdate>201512</startdate><enddate>201512</enddate><creator>González-Vacarezza, Nicolás</creator><creator>Poggi, Mariana</creator><creator>Arroyo, Gustavo</creator><creator>Muxi, Pablo</creator><creator>Alonso, Isabel</creator><creator>Rodríguez, Robinson</creator><creator>Díaz, Lilián</creator><creator>Signorelli, Silvana</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201512</creationdate><title>Equity in access to high cost drugs in Uruguay</title><author>González-Vacarezza, Nicolás ; Poggi, Mariana ; Arroyo, Gustavo ; Muxi, Pablo ; Alonso, Isabel ; Rodríguez, Robinson ; Díaz, Lilián ; Signorelli, Silvana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3156-cd2bf79c30ba3c8a2f896715316c0bb8c4ec3288d049c424a5b85059bd7741843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>access</topic><topic>drugs</topic><topic>equity</topic><topic>high-cost</topic><topic>Uruguay</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>González-Vacarezza, Nicolás</creatorcontrib><creatorcontrib>Poggi, Mariana</creatorcontrib><creatorcontrib>Arroyo, Gustavo</creatorcontrib><creatorcontrib>Muxi, Pablo</creatorcontrib><creatorcontrib>Alonso, Isabel</creatorcontrib><creatorcontrib>Rodríguez, Robinson</creatorcontrib><creatorcontrib>Díaz, Lilián</creatorcontrib><creatorcontrib>Signorelli, Silvana</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Value in health regional issues</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>González-Vacarezza, Nicolás</au><au>Poggi, Mariana</au><au>Arroyo, Gustavo</au><au>Muxi, Pablo</au><au>Alonso, Isabel</au><au>Rodríguez, Robinson</au><au>Díaz, Lilián</au><au>Signorelli, Silvana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Equity in access to high cost drugs in Uruguay</atitle><jtitle>Value in health regional issues</jtitle><addtitle>Value Health Reg Issues</addtitle><date>2015-12</date><risdate>2015</risdate><volume>8</volume><spage>122</spage><epage>128</epage><pages>122-128</pages><issn>2212-1099</issn><eissn>2212-1102</eissn><abstract>The aim of this study was to determine the equity in access to high cost oncology medicines reimbursed by the Uruguayan National Health System. Also, were determined the causes of access inequities. Different levels of access were determined by crossing epidemiological and reimbursement data with geographical distribution and number of Health System users. Possible causes of inequities were determined and weighted by Delphi technique. Access of patients assisted in the public sector to bevacizumab for metastatic colorectal cancer, rituximab for the treatment of non-Hodgkin lymphoma and trastuzumab for advanced HER2+ breast cancer, appears to be lower compared to patients assisted in private sector.Regarding rituximab for the treatment of non-Hodgkin lymphoma and trastuzumab for advanced HER2+ breast cancer, the results seem to show less access for patients residing outside the south region compared to those living in the south region.The main barriers to get reimbursement for patients living outside southern region are the access to pathological anatomy studies, imaging and other clinical analysis. Late diagnosis appears to be the main hurdles in access to these anti-cancer drugs, for patients assisted in the public sector. Equitable access to high cost drugs reimbursed by the National Health System requires policy decisions to address this issue.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29698164</pmid><doi>10.1016/j.vhri.2015.09.006</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2212-1099
ispartof Value in health regional issues, 2015-12, Vol.8, p.122-128
issn 2212-1099
2212-1102
language eng
recordid cdi_proquest_miscellaneous_2032397621
source EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects access
drugs
equity
high-cost
Uruguay
title Equity in access to high cost drugs in Uruguay
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T10%3A22%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Equity%20in%20access%20to%20high%20cost%20drugs%20in%20Uruguay&rft.jtitle=Value%20in%20health%20regional%20issues&rft.au=Gonz%C3%A1lez-Vacarezza,%20Nicol%C3%A1s&rft.date=2015-12&rft.volume=8&rft.spage=122&rft.epage=128&rft.pages=122-128&rft.issn=2212-1099&rft.eissn=2212-1102&rft_id=info:doi/10.1016/j.vhri.2015.09.006&rft_dat=%3Cproquest_cross%3E2032397621%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2032397621&rft_id=info:pmid/29698164&rft_els_id=S2212109915000679&rfr_iscdi=true